ImmunoCellular Therapeutics, Ltd. (IMUC)
-NYSE MKT 2.56 
0.01(0.39%) May 17, 4:01PM EDT
| Prev Close: | 2.57 |
|---|
| Open: | 2.60 |
|---|
| Bid: | 2.25 x 2000 |
|---|
| Ask: | 2.84 x 1000 |
|---|
| 1y Target Est: | 9.75 |
|---|
| Beta: | 1.37 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.54 - 2.60 |
|---|
| 52wk Range: | 1.51 - 4.00 |
|---|
| Volume: | 307,302 |
|---|
| Avg Vol (3m): | 475,195 |
|---|
| Market Cap: | 134.98M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.26 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IMMUNOCELLULAR THERAPEUTICS, LTD. FinancialsEDGAR Online Financials(Fri, May 17)
- ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine TargetBusiness Wire(Thu, May 16)
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemEDGAR Online(Tue, May 14)
- 3 Biotech Stocks With Potentialat Seeking Alpha(Tue, May 14)
- ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 2013at Seeking Alpha(Fri, May 10)
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- ImmunoCellular Therapeutics Announces First Quarter 2013 Financial ResultsBusiness Wire(Thu, May 9)
- Q1 2013 IMMUNOCELLULAR THERAPEUTICS Earnings Release - After Market CloseCCBN(Thu, May 9)
- Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward And Starting DC Vax Direct Trialsat Seeking Alpha(Tue, May 7)
- Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trialat Seeking Alpha(Fri, May 3)
- With A New Institutional Investor On Board, Northwest Biotherapeutics Breaks The Curseat Seeking Alpha(Wed, May 1)
- ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2013 May 9, 2013Business Wire(Wed, May 1)
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial StatementEDGAR Online(Thu, Apr 18)
- 2 Undervalued Immunotherapy Picksat Seeking Alpha(Mon, Apr 15)
- The 9 Levels Of Biotechnology And Who Should Invest: Part 2at Seeking Alpha(Mon, Apr 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.29 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors.
View More